Literature DB >> 20416954

Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus.

Erinn S Kellner1, Pui Y Lee, Yi Li, Juliana Switanek, Haoyang Zhuang, Mark S Segal, Eric S Sobel, Minoru Satoh, Westley H Reeves.   

Abstract

Patients with systemic lupus erythematosus (SLE) often suffer from depression and fatigue in addition to the physical manifestations of the autoimmune disease. Elevated production of type-I interferons (IFN-I) has been found in lupus patients and IFN-I can precipitate a variety of neuropsychiatric side effects. This study was conducted to evaluate the relationship between dysregulated IFN-I production and the presence of depression or fatigue in lupus patients. Through cross-sectional and longitudinal analysis we found no significant correlation between abnormal IFN-I levels (as measured by peripheral blood expression of IFN-I-stimulated genes) and neuropsychiatric manifestations. Elevation of endogenous serum IFN-I levels is unlikely to account for the depression and fatigue associated with SLE. Copyright 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20416954      PMCID: PMC3580233          DOI: 10.1016/j.jneuroim.2010.03.018

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  42 in total

Review 1.  Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.

Authors:  E Dieperink; M Willenbring; S B Ho
Journal:  Am J Psychiatry       Date:  2000-06       Impact factor: 18.112

2.  Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C.

Authors:  Eric Dieperink; Samuel B Ho; Lori Tetrick; Paul Thuras; Kulwinder Dua; Mark L Willenbring
Journal:  Gen Hosp Psychiatry       Date:  2004 May-Jun       Impact factor: 3.238

3.  Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.

Authors:  Xuebing Feng; Hui Wu; Jennifer M Grossman; Punchong Hanvivadhanakul; John D FitzGerald; Grace S Park; Xin Dong; Weiling Chen; Michelle H Kim; Haoling H Weng; Daniel E Furst; Alan Gorn; Maureen McMahon; Mihaela Taylor; Ernest Brahn; Bevra H Hahn; Betty P Tsao
Journal:  Arthritis Rheum       Date:  2006-09

4.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

5.  Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients.

Authors:  F Gilli; A Sala; C Bancone; P Salacone; M Gallo; E Gaia; A Bertolotto
Journal:  J Immunol Methods       Date:  2002-04-01       Impact factor: 2.303

6.  A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE).

Authors:  D D Gladman; M B Urowitz; A Ong; J Gough; A MacKinnon
Journal:  Lupus       Date:  1996-06       Impact factor: 2.911

7.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

8.  Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season.

Authors:  M Pertovaara; T Hasan; A Raitala; S S Oja; U Yli-Kerttula; M Korpela; M Hurme
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

Review 10.  Interferons, interferon-like cytokines, and their receptors.

Authors:  Sidney Pestka; Christopher D Krause; Mark R Walter
Journal:  Immunol Rev       Date:  2004-12       Impact factor: 12.988

View more
  5 in total

1.  Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Authors:  John G Hanly; Li Su; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Michelle Petri; Ian N Bruce; M A Dooley; Paul Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Kristjan Steinsson; Rosalind Ramsey-Goldman; Munther A Khamashta; Cynthia Aranow; Graciela S Alarcón; Barri J Fessler; Susan Manzi; Ola Nived; Gunnar K Sturfelt; Asad A Zoma; Ronald F van Vollenhoven; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Kenneth C Kalunian; Murat Inanc; Diane L Kamen; Christine A Peschken; Soren Jacobsen; Anca Askanase; Chris Theriault; Kara Thompson; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2015-07       Impact factor: 10.995

Review 2.  Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.

Authors:  Theophanis P Karageorgas; Dimitrios D Tseronis; Clio P Mavragani
Journal:  J Biomed Biotechnol       Date:  2011-11-16

3.  Depression in Patients with Systemic Lupus Erythematosus: A Multicenter Study.

Authors:  Ibrahim Abdulrazag Al-Homood; Narges E Omran; Abdulrahman S Alwahibi; Maha Aldosoghy; Amal Alharthy; Ghassan S Aljohani
Journal:  Saudi J Med Med Sci       Date:  2017-08-21

4.  Fatigue and cognitive function in systemic lupus erythematosus: associations with white matter microstructural damage. A diffusion tensor MRI study and meta-analysis.

Authors:  S J Wiseman; M E Bastin; I F Hamilton; D Hunt; S J Ritchie; E N Amft; S Thomson; J F F Belch; S H Ralston; J M Wardlaw
Journal:  Lupus       Date:  2016-09-29       Impact factor: 2.911

5.  Silent Burdens in Disease: Fatigue and Depression in SLE.

Authors:  R Fonseca; M Bernardes; G Terroso; M de Sousa; M Figueiredo-Braga
Journal:  Autoimmune Dis       Date:  2014-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.